When a patient arrives with low platelets and signs of red blood cell destruction, doctors face a race against time. Thrombotic thrombocytopenic purpura (TTP), a rare but life-threatening blood disorder, requires treatment within hours, not days, yet the test that confirms it (ADAMTS13 activity) can take days to return from the lab. This is where the PLASMIC score becomes essential.
The PLASMIC score is a 7-point clinical prediction tool that estimates the probability that a patient has severe ADAMTS13 deficiency, the defining feature of TTP, using only the patient's history and routine blood test results [1]. It does not require any specialized testing, which makes it fast and widely accessible, even in hospitals without rapid ADAMTS13 testing capability.
The score is primarily used by emergency physicians, hematologists, internal medicine teams, and apheresis or transfusion medicine specialists. When a patient presents with thrombocytopenia and hemolysis (red blood cell breakdown), these clinicians use the PLASMIC score to decide how urgently to start plasma exchange, the cornerstone treatment for TTP, while waiting for confirmatory lab results.
How the PLASMIC Score Works
PLASMIC is a mnemonic. Each letter represents one of the seven clinical criteria used to calculate the score. One point is given for each criterion the patient meets [1,2]:
| Letter | Criterion | Point Awarded If |
|---|---|---|
|
P
|
Platelet count | Below 30,000/µL |
|
L
|
Lysis (hemolysis marker) | Reticulocyte count above 2.5%, indirect bilirubin above 2 mg/dL, or undetectable haptoglobin |
|
A
|
Active cancer | No active cancer history (within the past year) |
|
S
|
Stem cell or solid organ transplant | No prior transplant history |
|
M
|
MCV (mean corpuscular volume) | Below 90 fL |
|
I
|
INR (international normalized ratio) | Below 1.5 |
|
C
|
Creatinine | Below 2.0 mg/dL |
Each criterion contributes one point, for a maximum possible score of 7. The logic behind each variable matters: a low platelet count and hemolysis are direct signs of TTP's destructive process, while the absence of cancer, transplant history, kidney impairment, or coagulation abnormality helps rule out other causes of similar-looking blood test results, such as disseminated intravascular coagulation (DIC) or cancer-associated microangiopathy [4].
PLASMIC Score Calculator
PLASMIC Score Calculator
Predicts the probability of severe ADAMTS13 deficiency in suspected TTP. Check all that apply:
Interpreting the PLASMIC Score
Once calculated, the score places patients into one of three risk categories, each linked to a different probability of severe ADAMTS13 deficiency [1,2]:
| Score | Risk Category | Approx. Probability of Severe ADAMTS13 Deficiency | Recommended Action |
|---|---|---|---|
| 0–4 | Low risk | Around 0–4% | Consider alternative diagnoses; ADAMTS13 testing may be deferred |
| 5 | Intermediate risk | Around 5–57% | Send ADAMTS13 testing, monitor closely, seek expert consultation |
| 6–7 | High risk | Greater than 70–90% | Send ADAMTS13 testing, but begin plasma exchange immediately without waiting for results |
This stepped approach matters clinically. Validation studies have shown the PLASMIC score has excellent discrimination, with an area under the curve (AUC) of approximately 0.94, alongside a high negative predictive value (around 98%) [2]. In plain terms, a low score is very reliable for ruling TTP out, while a high score should prompt immediate treatment, since delaying plasma exchange in true TTP significantly increases the risk of death.
It is important to remember that the PLASMIC score estimates probability, not certainty. It is a bridging tool used alongside clinical judgment, not a replacement for ADAMTS13 testing, which remains the definitive diagnostic test [3]. Additionally, clinicians must exercise caution when applying the PLASMIC score to pregnant patients. Because the original derivation cohort excluded pregnancy, physiological changes during gestation can alter baseline creatinine and coagulation parameters, potentially reducing the score's specificity.
While a score of 5 or higher in a pregnant patient still provides very high sensitivity and strongly supports urgent intervention, clinical judgment remains paramount in distinguishing TTP from other pregnancy-associated microangiopathies like preeclampsia or HELLP syndrome [5].
Case Scenarios
Scenario 1: Low-Risk Score
A 58-year-old man is admitted with fatigue and mild bruising. His labs show a platelet count of 85,000/µL, normal MCV, INR of 1.2, creatinine of 1.1 mg/dL, and no signs of hemolysis. He has a history of lung cancer treated six months ago.
Applying the PLASMIC criteria: his platelet count does not meet the threshold (no point), there is no hemolysis (no point), and he has a recent active cancer history (no point). His total score is low, likely 2 or 3.
Interpretation: A low score in this context, combined with his cancer history, points away from TTP and toward an alternative explanation for his thrombocytopenia, such as chemotherapy-related bone marrow suppression. ADAMTS13 testing may reasonably be deferred while other causes are investigated [1].
Case Scenario 2: High-Risk Score
A 34-year-old woman with no significant medical history presents to the emergency department with confusion and petechiae (small bruise-like skin spots). Her labs show a platelet count of 12,000/µL, hemoglobin of 7.8 g/dL with schistocytes (fragmented red blood cells) on the blood smear, reticulocyte count of 4.1%, MCV of 86 fL, INR of 1.1, and creatinine of 0.9 mg/dL. She has no cancer or transplant history.
Applying the PLASMIC criteria: her platelet count meets the threshold (1 point), she has clear hemolysis (1 point), no active cancer (1 point), no transplant history (1 point), MCV below 90 fL (1 point), INR below 1.5 (1 point), and creatinine below 2.0 mg/dL (1 point). Her total score is 7, the maximum possible.
Interpretation: This score places her in the high-risk category, with a probability of severe ADAMTS13 deficiency exceeding 70-90%. Per guideline recommendations, plasma exchange should begin immediately, without waiting for ADAMTS13 results, given the high mortality risk of untreated TTP [1,3]. Furthermore, based on current clinical practice guidelines, a high-risk PLASMIC score should prompt the consideration of adding caplacizumab (a targeted anti-von Willebrand factor nanobody) alongside plasma exchange and corticosteroids. Initiating caplacizumab early, even before the ADAMTS13 results return, has been shown to rapidly halt microthrombi formation, accelerate platelet recovery, and reduce overall hospital stays [6].
Disclaimer: This article is intended for educational and informational purposes only. It is not intended to be a substitute for informed professional medical advice, diagnosis, or treatment. While the information presented here is derived from credible medical sources and is believed to be accurate and up-to-date, it is not guaranteed to be complete or error-free. See additional information.
References
- Bendapudi, P. K., Hurwitz, S., Fry, A., Marques, M. B., Waldo, S. W., Li, A., Sun, L., Upadhyay, V., Hamdan, A., Brunner, A. M., Gansner, J. M., Viswanathan, S., Kaufman, R. M., Uhl, L., Stowell, C. P., Dzik, W. H., & Makar, R. S. (2017). Derivation and external validation of the PLASMIC score for rapid assessment of adults with thrombotic microangiopathies: a cohort study. The Lancet. Haematology, 4(4), e157–e164. https://doi.org/10.1016/S2352-3026(17)30026-1
- Li, A., Khalighi, P. R., Wu, Q., & Garcia, D. A. (2018). External validation of the PLASMIC score: a clinical prediction tool for thrombotic thrombocytopenic purpura diagnosis and treatment. Journal of thrombosis and haemostasis : JTH, 16(1), 164–169. https://doi.org/10.1111/jth.13882
- Paydary, K., Banwell, E., Tong, J., Chen, Y., & Cuker, A. (2020). Diagnostic accuracy of the PLASMIC score in patients with suspected thrombotic thrombocytopenic purpura: A systematic review and meta-analysis. Transfusion, 60(9), 2047–2057. https://doi.org/10.1111/trf.15954
- Sukumar, S., Lämmle, B., & Cataland, S. R. (2021). Thrombotic Thrombocytopenic Purpura: Pathophysiology, Diagnosis, and Management. Journal of clinical medicine, 10(3), 536. https://doi.org/10.3390/jcm10030536
- Kumar, V., Madeswaran, C., Sunkesula, V., & Kundrapu, S. (2026). Pregnancy-Associated Thrombotic Thrombocytopenic Purpura: Diagnostic Pitfalls, Therapeutic Strategies, and Emerging Paradigms. Biomedicines, 14(2), 441. https://doi.org/10.3390/biomedicines14020441.
- DutScully, M., Rayment, R., Clark, A., Westwood, J. P., Cranfield, T., Gooding, R., Bagot, C. N., Taylor, A., Sankar, V., Gale, D., Dutt, T., McIntyre, J., Lester, W., & BSH Committee (2023). A British Society for Haematology Guideline: Diagnosis and management of thrombotic thrombocytopenic purpura and thrombotic microangiopathies. British journal of haematology, 203(4), 546–563. https://doi.org/10.1111/bjh.19026
